Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Passage Bio
PASG
$14.7M
| $2.5M | ﹤0.01% |
12,536
+2,685
| +27% | +$640K |
|
2652
eGain
EGAN
$206M
| $2.5M | ﹤0.01% |
244,795
-30,970
| -11% | -$350K |
|
2653
RPC Inc
RES
$1.39B
| $2.49M | ﹤0.01% |
512,550
+94,148
| +23% | +$394K |
|
2654
NetEase
NTES
$78.5B
| $2.48M | ﹤0.01% |
29,041
-462,459
| -94% | -$43.7M |
|
2655
Lyell Immunopharma
LYEL
$337M
| $2.46M | ﹤0.01% |
+8,313
| New | +$2.49M |
|
2656
Latham Group
SWIM
$889M
| $2.44M | ﹤0.01% |
148,746
+2,148
| +1% | +$50.1K |
|
2657
Greif Class B
GEF.B
$4.22B
| $2.41M | ﹤0.01% |
37,122
-64
| -0.2% | -$3.93K |
|
2658
Babcock & Wilcox
BW
$1.39B
| $2.4M | ﹤0.01% |
374,423
-55,397
| -13% | -$387K |
|
2659
Frontline
FRO
$9.02B
| $2.39M | ﹤0.01% |
254,747
+1,540
| +0.6% | +$12.2K |
|
|
CASA
2660
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $2.37M | ﹤0.01% |
348,673
+4,516
| +1% | +$33.3K |
|
|
BDSI
2661
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $2.36M | ﹤0.01% |
654,297
+1,412
| +0.2% | +$5.33K |
|
2662
PagSeguro Digital
PAGS
$2.43B
| $2.36M | ﹤0.01% |
45,555
+17,795
| +64% | +$998K |
|
2663
Immunovant
IMVT
$8.64B
| $2.34M | ﹤0.01% |
269,378
-65,058
| -19% | -$587K |
|
|
CMBM
2664
DELISTED
Cambium Networks
CMBM
| $2.34M | ﹤0.01% |
64,526
+32,930
| +104% | +$1.3M |
|
2665
Futu Holdings
FUTU
$14.7B
| $2.33M | ﹤0.01% |
25,538
| – | – |
|
2666
Forestar Group
FOR
$1.51B
| $2.31M | ﹤0.01% |
123,859
+6,484
| +6% | +$131K |
|
2667
Lexicon Pharmaceuticals
LXRX
$1.04B
| $2.29M | ﹤0.01% |
475,794
+6,090
| +1% | +$25K |
|
2668
Aclaris Therapeutics
ACRS
$863M
| $2.29M | ﹤0.01% |
126,916
+19,078
| +18% | +$306K |
|
|
IAS
2669
DELISTED
Integral Ad Science
IAS
| $2.27M | ﹤0.01% |
+109,968
| New | +$2.17M |
|
2670
Mercer International
MERC
$33.8M
| $2.26M | ﹤0.01% |
195,179
+5,888
| +3% | +$68.3K |
|
2671
Rush Enterprises Class B
RUSHB
$9.37B
| $2.24M | ﹤0.01% |
73,415
-94
| -0.1% | -$2.65K |
|
2672
Energy Fuels
UUUU
$3.64B
| $2.23M | ﹤0.01% |
317,207
+17,898
| +6% | +$102K |
|
|
XOG
2673
DELISTED
Extraction Oil & Gas, Inc. Common Stock
XOG
| $2.23M | ﹤0.01% |
39,445
+6,308
| +19% | +$302K |
|
2674
El Pollo Loco
LOCO
$471M
| $2.21M | ﹤0.01% |
130,976
-439
| -0.3% | -$7.93K |
|
|
ROCC
2675
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
| $2.21M | ﹤0.01% |
82,798
-21,841
| -21% | -$430K |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.